{"name":"BeiGene","slug":"beigene","ticker":"BGNE","exchange":"NASDAQ","domain":"beigene.com","description":"BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.","hq":"Beijing, China / Cambridge, MA","founded":0,"employees":"","ceo":"John V. Oyler","sector":"Oncology / Global Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$25B","metrics":{"revenue":3600000000,"revenueGrowth":1211.7,"grossMargin":0,"rdSpend":2145868000,"netIncome":286933000,"cash":8188573000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[{"name":"Brukinsa","genericName":"BGB-3111","slug":"bgb-3111","revenue":2700000000,"yoyGrowth":0,"percentOfTotal":75},{"name":"Tevimbra","genericName":"TISLELIZUMAB","slug":"tislelizumab","revenue":900000000,"yoyGrowth":0,"percentOfTotal":25}],"timeline":[{"date":"2019-01-01","label":"Brukinsa first approved","drug":"Brukinsa","drugSlug":"bgb-3111","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Tevimbra first approved","drug":"Tevimbra","drugSlug":"tislelizumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-04-22","label":"TEVIMBRA Phase 3 readout (Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma)","drug":"TEVIMBRA","drugSlug":"islelizumab-jsgr","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-11-01","label":"TEVIMBRA Phase 3 readout (Colorectal Cancer, Microsatellite Instability High)","drug":"TEVIMBRA","drugSlug":"islelizumab-jsgr","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-06-01","label":"Brukinsa patent cliff ($1.4B at risk)","drug":"Brukinsa","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":3600000000,"percentOfTotal":100,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"Brukinsa","genericName":"BGB-3111","slug":"bgb-3111","indication":"Chronic lymphoid leukemia, disease","status":"marketed","revenue":2700000000},{"name":"Tevimbra","genericName":"TISLELIZUMAB","slug":"tislelizumab","indication":"Esophageal Cancer","status":"marketed","revenue":900000000},{"name":"Brukinsa","genericName":"ZANUBRUTINIB","slug":"zanubrutinib","indication":"Mantle cell lymphoma (MCL)","status":"marketed"},{"name":"BGB-15025","genericName":"BGB-15025","slug":"bgb-15025","indication":"Acute myeloid leukemia (AML) with NPM1 mutation or MLL rearrangement","status":"phase_3"},{"name":"BGB-290","genericName":"BGB-290","slug":"bgb-290","indication":"Urothelial carcinoma","status":"phase_2"},{"name":"BGB-A445","genericName":"BGB-A445","slug":"bgb-a445","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"BGB-DXP593","genericName":"BGB-DXP593","slug":"bgb-dxp593","indication":"Solid tumors","status":"phase_2"},{"name":"Chemotherapy Doublet","genericName":"Chemotherapy Doublet","slug":"chemotherapy-doublet","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"LBL-007","genericName":"LBL-007","slug":"lbl-007","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"Pamiparib capsule","genericName":"Pamiparib capsule","slug":"pamiparib-capsule","indication":"Ovarian cancer (BRCA-mutated or HRD-positive)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"immunology","drugs":[{"name":"BGB-10188","genericName":"BGB-10188","slug":"bgb-10188","indication":"Other","status":"phase_1"},{"name":"BGB-11417","genericName":"BGB-11417","slug":"bgb-11417","indication":"Other","status":"phase_2"},{"name":"BGB-283","genericName":"BGB-283","slug":"bgb-283","indication":"Other","status":"phase_1"},{"name":"BGB-45035","genericName":"BGB-45035","slug":"bgb-45035","indication":"Other","status":"phase_2"},{"name":"BGB-A425","genericName":"BGB-A425","slug":"bgb-a425","indication":"Other","status":"phase_2"},{"name":"BGB-C354","genericName":"BGB-C354","slug":"bgb-c354","indication":"Other","status":"phase_1"},{"name":"Concurrent Chemoradiotherapy","genericName":"Concurrent Chemoradiotherapy","slug":"concurrent-chemoradiotherapy","indication":"Other","status":"phase_2"},{"name":"TEVIMBRA","genericName":"islelizumab-jsgr","slug":"islelizumab-jsgr","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Brukinsa","genericName":"BGB-3111","slug":"bgb-3111","phase":"marketed","mechanism":"Brukinsa blocks the BTK protein, which is involved in the activation of B cells.","indications":["Chronic lymphoid leukemia, disease","Mantle cell lymphoma","Marginal zone lymphoma","Waldenström macroglobulinemia"],"catalyst":""},{"name":"Tevimbra","genericName":"TISLELIZUMAB","slug":"tislelizumab","phase":"marketed","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.","indications":["Esophageal Cancer","Gastric Cancer","Esophageal Squamous Cell Carcinoma","Gastric or gastroesophageal junction adenocarcinoma","Unresectable or metastatic esophageal squamous cell carcinoma"],"catalyst":""},{"name":"Brukinsa","genericName":"ZANUBRUTINIB","slug":"zanubrutinib","phase":"marketed","mechanism":"Small molecule","indications":["Mantle cell lymphoma (MCL)","Waldenström's macroglobulinemia (WM)","Marginal zone lymphoma (MZL)","Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","Follicular lymphoma (FL)"],"catalyst":""},{"name":"BGB-10188","genericName":"BGB-10188","slug":"bgb-10188","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BGB-11417","genericName":"BGB-11417","slug":"bgb-11417","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BGB-15025","genericName":"BGB-15025","slug":"bgb-15025","phase":"phase_3","mechanism":"BGB-15025 is a selective inhibitor of menin that disrupts the interaction between menin and mixed-lineage leukemia (MLL) proteins, restoring normal gene expression in acute leukemias.","indications":["Acute myeloid leukemia (AML) with NPM1 mutation or MLL rearrangement","Acute lymphoblastic leukemia (ALL) with MLL rearrangement"],"catalyst":""},{"name":"BGB-283","genericName":"BGB-283","slug":"bgb-283","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BGB-290","genericName":"BGB-290","slug":"bgb-290","phase":"phase_2","mechanism":"PARP inhibitor","indications":["Urothelial carcinoma"],"catalyst":""},{"name":"BGB-45035","genericName":"BGB-45035","slug":"bgb-45035","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BGB-A425","genericName":"BGB-A425","slug":"bgb-a425","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BGB-A445","genericName":"BGB-A445","slug":"bgb-a445","phase":"phase_3","mechanism":"BGB-A445 is a Bcl-2 inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)","Follicular lymphoma"],"catalyst":""},{"name":"BGB-C354","genericName":"BGB-C354","slug":"bgb-c354","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BGB-DXP593","genericName":"BGB-DXP593","slug":"bgb-dxp593","phase":"phase_2","mechanism":"BGB-DXP593 is a small molecule inhibitor targeting the CD73 enzyme.","indications":["Solid tumors"],"catalyst":""},{"name":"Chemotherapy Doublet","genericName":"Chemotherapy Doublet","slug":"chemotherapy-doublet","phase":"phase_2","mechanism":"Chemotherapy agents work by interfering with DNA replication and cell division, leading to cell death.","indications":["Non-small cell lung cancer","Small cell lung cancer","Breast cancer","Lymphoma"],"catalyst":""},{"name":"Concurrent Chemoradiotherapy","genericName":"Concurrent Chemoradiotherapy","slug":"concurrent-chemoradiotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LBL-007","genericName":"LBL-007","slug":"lbl-007","phase":"phase_3","mechanism":"LBL-007 is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell and myeloid cell activation in hematologic malignancies.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)"],"catalyst":""},{"name":"Pamiparib capsule","genericName":"Pamiparib capsule","slug":"pamiparib-capsule","phase":"phase_3","mechanism":"Pamiparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and causing cancer cell death.","indications":["Ovarian cancer (BRCA-mutated or HRD-positive)","Breast cancer (BRCA-mutated)","Gastric cancer (HRD-positive)"],"catalyst":""},{"name":"TEVIMBRA","genericName":"islelizumab-jsgr","slug":"islelizumab-jsgr","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"earnings","headline":"BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"BeiGene reported its fourth quarter and full year 2022 financial results, with revenue of $1.4 billion and a net loss of $1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2022-12-23","type":"deal","headline":"BeiGene and Novartis Announce Global Collaboration to Develop and Commercialize Tislelizumab in China","summary":"BeiGene and Novartis announced a global collaboration to develop and commercialize tislelizumab in China.","drugName":"","sentiment":"positive"},{"date":"2022-08-05","type":"regulatory","headline":"FDA Approves Tislelizumab for Certain Types of Blood Cancer","summary":"The FDA approved tislelizumab for the treatment of certain types of blood cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPYno5bDVodmhJOThwOGs3SklWZXd3MHJUWUM4QmtmNmhsa1czM1pzRHBMeWpHbHVBSTl1MjVsbFRUdlZuSmExX1N1azBkUkNPbl9MSjRQRWhvdXUtaTlmNGtvMjljZFkzeWZ5Z200NURkckhTUG5fWmZIVFVJUjZoYXBTZDlRUGV0aWNEbUxLWDlJd3labHB2NE0wZzVaMl9hNUdOa2w2R1VsSjZFMGFvUUZOX0J6YjRUZTdQUGtzZE5UbjB0RUE?oc=5","date":"2026-03-23","type":"pipeline","source":"AD HOC NEWS","summary":"Bloom Energy Corp (NYSE - replacing with BGNE) stock faces pressure amid biotech sector volatility a - AD HOC NEWS","headline":"Bloom Energy Corp (NYSE - replacing with BGNE) stock faces pressure amid biotech sector volatility a","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE45OWZ5cEwwTjI3RTVneDA4cDNVMy16Si1RSDdKWUkzXzZtam5yelN6YWFFdzNtQkdCZ0txTWNRd2plandMenoxUEhaWTVUSHFMYzln?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"BGNE Stock Price, News & Analysis | Beigene - Stock Titan","headline":"BGNE Stock Price, News & Analysis | Beigene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPV3pmSHV5bWZMYjI4WS05NnFWeUI1cWxaV0JORF82cW5aRE1VeTIyb0FobmJfT0FzVlQ2TmwwVy1TSDRUdXdUSjNVQm9LelFQRDNwNU5waHl1YWNxc0RmVWEwRDVGbTNGbGVWMWh0NDZPX01GbHNCRDVyYWxuSmJBZWRqdFQzZllTWjJ6M0xDV0ZuaEtRbUZyVVRxbU5qVllIazhpYzY0bHU?oc=5","date":"2025-01-16","type":"pipeline","source":"The Pharma Letter","summary":"With tislelizumab, BeiGene brings immunotherapy to more patients in Europe - The Pharma Letter","headline":"With tislelizumab, BeiGene brings immunotherapy to more patients in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9wZ1l3MWs5R1VoYWtwelR4TDFxaUcwMjJ6VnV6V1ZkSE9mYS1pd0I3bC1HVTZzQ1hHUzJ3eTJvcnlYVlZCZWRVWXRJWW44NmJDakxfbHZMUTdaYzNsbTNkY19LSU9pRVhZUGFPUTlWU0N0WkIwYXhTUUt3ay0?oc=5","date":"2024-12-02","type":"pipeline","source":"Yahoo Finance","summary":"Why Is BeiGene, Ltd. (BGNE) Among the Best High Growth Healthcare Stocks to Invest In Now? - Yahoo Finance","headline":"Why Is BeiGene, Ltd. (BGNE) Among the Best High Growth Healthcare Stocks to Invest In Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQTGR4aWZMNlB2R1gwTXZZXy1tMUdlaEhMWkFwWm9lLTEtZzBWX3dTU2tQSTE5NTFDVXlxWTc1QlRlakVHcmZlNTZSTWhnZmZFMjFUbEZSRmdrU3NKaHdLOGJTeU5mWHE3YTNIWnJDazlwZU95MEN1RDh2ZWcxemxtQnJUbVpPZmp1QV9IczlhR19nT09fenZsNHRHajIxYUw5TUNnNTA0X3dOZ0lTSmdvOVZPN05DM0RndUE5OUg2b2g2cTFqcmphYVoxOWk0QnJ5Q19SUHRlNWVGX0t2WUNOLW5IV3cxVlVTaVZyYTZGa1pNSDdlRkpOTzY0SWpOclExYlFRWGN0Y28?oc=5","date":"2024-11-14","type":"pipeline","source":"Business Wire","summary":"BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer - Business Wire","headline":"BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOMmRlckFhbDU5b01yckwyRE0tbUFoZF9LdTRvUmdWNlRIT1dRWWtRbkJMR3kwRUE5Q2NPSjhFc1k1ejhwdXA5MG44akhldTVLZUdqYi1FYlZSM0RZeGU2M1V1VUpKTzJwRDBpYks5eXZXNEFXXzlCWWxyRFIxSG5kWDR2ZXNOWHZXNzNJQlRtOFl6TDFZcVhBR0tDME4tdW9SeU5UZnhNWklOSDB6QlQ5Wg?oc=5","date":"2024-10-07","type":"pipeline","source":"The Pharma Letter","summary":"BeiGene enters competitive checkpoint blocker market with Tevimbra - The Pharma Letter","headline":"BeiGene enters competitive checkpoint blocker market with Tevimbra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxQRzVfbWliUXdjRHV5T0hqYlh0UGZLYXktVUdmYUtDU1RtZ2prelVkZVhPRVEwYmozSklMZWZfd2ZIY2VlRUpELXZFaXo5QlZGOVdIZWZYRjNTNExqY1plY2tubkFhcHdrRmoxNWpPTlR5SHBVQzZRRWR3NDgtTHExaE9SRTd0eTJBVXNDdmdzOGJpS3F2b2hRaEg4enFYUFFMbUdfZW9VUGJaRlBESlF0SzFaSE1EcVBUbGZhOFdSNjJDVVN0U3ZPZl8zSHhhMjVsSG4xNjJVS0VvQW1MVlJEQTY5dzFCYkxySGZQenFmUkNKTzJmbTZZRUVKZzJ4V3U1bFBZY1NFVVUzNXNfREZDcTV2U19JRXBvQmZOcFNNZWVyY3BlN1kwalJzcng?oc=5","date":"2024-06-13","type":"deal","source":"Business Wire","summary":"BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region - Business Wire","headline":"BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Midd","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxONWViZmhpdjlxR2VqZkdnbGJTNGh5QmZLcDhneGhnamJ5T1NxY3FnX2l6LTlvZDdGQkJkclMzY2x3TXZWaGxEU0JJcG9iT1hQXzJNaFBNVjVWNzBURDhYdk1ucEJTTU1fZVp5TGhvb3YyU3NlR0ZOdnhycERod1RGVzBWVGRnbWF3MDAxbUhVOUl3ZE1iSDZpUUpQcTA2bWhnd3QwUC04aHVFdk00amJIZGJwbThiTFo4cTB4MHdEanFScU9ENFVObmNXY0N6LUlUelVlQXY1eGZvOXRL?oc=5","date":"2024-05-21","type":"deal","source":"BioPharma APAC","summary":"BeiGene and Glenmark Forge Strategic Partnership to Distribute Innovative Cancer Treatments in India - BioPharma APAC","headline":"BeiGene and Glenmark Forge Strategic Partnership to Distribute Innovative Cancer Treatments in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbG1feGdWNkt4UE8tSUpvNS1Qd244YXUyZHItUWh4WjlDNGllWFFMbzJnQk9xdHd3WGs3R2tKWHJiWXJfNTFhU0FjajhvMkJsdHJpRmVURTBTMW5qNV9hNS10Nmx4LXdXMHRLQ3h1ZGlBQzZmUVVmSHNRTUQ4VVlqZXBRaUp6MU0tbWl4WUdTSmZEdzhsU0J1UGZlSVp2cUM0NGE1TGlSZWR4QQ?oc=5","date":"2022-03-14","type":"pipeline","source":"Morningstar Australia","summary":"These Chinese stocks are at risk of being delisted from US exchanges - Morningstar Australia","headline":"These Chinese stocks are at risk of being delisted from US exchanges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9mUDlQSGVOR2hSSGFmZW02WV9LRHY0cmJvQlh2R2I5c3pmNnAyM0VqTW96STlkYzgxSmlmcEpFeF90Wk43c3RwMEdiZUJobXRQS25kSlNJZzlpT1U?oc=5","date":"2021-12-20","type":"pipeline","source":"TradingView","summary":"688235 Stock Price and Chart — SSE:688235 - TradingView","headline":"688235 Stock Price and Chart — SSE:688235","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxNcE1ndDBKRmtBdW1raE95TXM1cmVfcG5EejJ6SXQ0alVtd1c2Nm1OZUF6Qi1fQ1cwNDU5eU5maXExemwtQTNmSHlOM3I5aFNmOGJBcFZUUXRuTEhxVlBLVEJoUXZrN0d3c2xUY01YYWpfLWRjakpYZkxJeW9nT3ppdWpDa2lXWHZsTUlOZXlHd1VadGFERG9vUkZqQ0YtQTBuSFNybUNIbmZSUnNWTVhEaGdERjBGd2twWEp1MzgzNkx3bHNYRDZfQXlCVDgxTFplVGs3eDVzVjhSNzFLZmpKNlNGQ21yWnF4N1EtNjJjZ3F4SUhWMFV5cnZBYmtMa0RNUHJZSWJESEl6Z2pQM1Q2cklBVElZNXg1eDU4ZmdCdVFXVDRF?oc=5","date":"2021-12-03","type":"regulatory","source":"Via TT","summary":"BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT ® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease - Via TT","headline":"BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT ® (Siltuximab for Injection) in China for Idiopathic Multicent","sentiment":"positive"}],"patents":[{"drugName":"Brukinsa","drugSlug":"zanubrutinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":18,"phaseCounts":{"marketed":4,"phase_1":3,"phase_2":7,"phase_3":4},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":238387000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":238387000,"period":"2017-12-31"},{"value":18174000,"period":"2017-12-31"},{"value":220213000,"period":"2017-09-30"},{"value":1070000,"period":"2016-12-31"},{"value":1070000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":2145868000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":286933000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":8188573000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}